Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, and Cutaneous Melanoma Detection and Management.
RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)
Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Metastatic Melanoma
Single-Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T-cell Subpopulation That Is Correlated with Response to Checkpoint Therapy in Melanoma
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.
Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response
Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with <i>BRAF V600</i>-mutated solid tumors.
Abstract CT003: Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)
Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309).
Systemic Therapy for Melanoma: ASCO Guideline Update
Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy
A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with <i>BRAFv600</i>-mutated solid tumors.
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies
Loneliness and symptom burden in oncology patients during the COVID‐19 pandemic
Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors
Systemic Therapy for Melanoma: ASCO Guideline
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients
Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Multidisciplinary Management of Cancer During Pregnancy
Oncology patients’ perceptions of and experiences with COVID-19
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab